B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co
Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patients. MELSUNGEN, Germany and MONMOUTH JUNCTION, N.J., March 2, 2021 /PRNewswire/ — B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation […]
In this image released on Tuesday, March 2, 2021, the CytoSorb® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream. B. Braun Avitum
Organization, Facts & Figures
In this image released on Tuesday, March 2, 2021, the OMNI® extracorporeal platform is intended to perform continuous blood purification treatments and therapeutic plasma exchange. The OMNI® in combination with OMNIset®* disposable
A Month's-End Associated Press (AP) Photographic Celebration Of
Promoting Management and Leadership
Organization, Facts & Figures
Company
Continuous Renal Replacement Therapy Market Size, Share, Industry Forecast by 2032
Canon Medical Systems Europe Partners with Athletic Bilbao FC
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote th - English
Digital Diabetes Management Market Size, Trends & Forecast
Nouvelles officielles de Cooperation 2024
